ClinicalTrials.gg
TerminatedNCT02227368TI-PAD EVRUpdated Jul 19, 2017Results posted

Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR

A Phase 2 interventional study of Ticagrelor and Comparator in Peripheral Artery Disease (PAD), sponsored by AstraZeneca. Terminated at 10 sites in United States. Open to participants aged 50 Years to 130 Years. Per ClinicalTrials.gov, last updated 2017-07-19.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
50 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing ticagrelor in Peripheral Arterial Disease — 1 open to participants now, 2 under way, none of them phase 3. Ticagrelor · Peripheral Arterial Disease.

Enrollment
7th of 10
40 · median 58
Started
2014
with 2 others
Phase 2
Only one
of the 10
Registered
3rd of 10
by date
Lead sponsor
3 of 10
AstraZeneca

Among the 10 studies testing ticagrelor in Peripheral Arterial Disease, this one is the 7th largest by enrollment, is one of 3 that started in 2014, is the only one in phase 2, and was the 3rd registered.

Peripheral Arterial Disease

1,377 studies on the registry are indexed under Peripheral Arterial Disease; 275 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

1 of the 10 studies testing ticagrelor in Peripheral Arterial Disease is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About ticagrelor

Ticagrelor: first FDA approval 2011 (BRILINTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 192 Peripheral Arterial Disease studies recruiting now, 138 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 50 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing ticagrelor in Peripheral Arterial Disease, or all of them as a file.
02

Study summary

To compare the effect of ticagrelor versus aspirin on the change in peak walking time, evaluated on the graded treadmill test, from one to 26 weeks post-revascularization in patients with peripheral artery disease who have undergone endovascular revascularization for moderate to severe claudication or ischemic rest pain.

Read the detailed description

A Phase II Multicentre, Randomised, Double-Blind, Controlled, Parallel-Group Study to Evaluate the Walking Time Effect of Long-Term Ticagrelor in Comparison to Long-Term Aspirin Administration in Ambulatory Patients with Peripheral Artery Disease Undergoing Endovascular Revascularization - The Ticagrelor in Peripheral Artery Disease Endovascular Revascularization Study TI-PAD I EVR.

03

Conditions studied

  • Peripheral Artery Disease (PAD)

Keywords

  • Myocardial Infarction
  • Peripheral Arterial disease
  • Mycardial Ischemia
  • Heart Diseases
  • Cardiovascular Diseases
  • Vascular Diseases
  • Altherosclerosis
  • Arteriosclerosis
  • Arterial Occlusive Diseases
  • Peripheral Vascular Diseases
  • Ticagrelor
  • Ticlopidine
  • Platelet Aggregation inhibitors
  • Hematologic Agents
  • Therapeutic Uses
  • Pharmacologic Actions
  • Purinegic P2Y Receptor Antagonists
  • Purinegic P2 Receptor Antagonists
  • Purinergic Antagonists
  • Purinergic Agents
  • Neurotransmitter Agents
  • Molecular Mechanisms of Pharmacological Actions
  • Physiological Effects of Drugs
  • Fibrinolytic Agents
  • Crardiovascular Agents
04

Who can participate

Ages eligible
50 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written prior to any study specific procedures.
  2. Ambulatory male or female outpatients aged 50 years of age or older at the time of the Screening Visit.
  3. EVR, below the inguinal ligament that includes the distal SFA and/or popliteal and/or tibial arteries, that is planned to occur within 5 weeks after the Screening Visit, as determined and clearly documented by the Principal Investigator or physician Sub-Investigator (MD/DO). Patients undergoing a proximal revascularization may be enrolled as long as their procedure also includes treating the distal SFA, popliteal or tibial arteries. The EVR must be confirmed as technically successful (a completed procedure where haemostasis has been achieved) before the patient is randomised.
  4. Normal inflow into the lower extremity as determined by the Principal Investigator or physician Sub-Investigator (MD/DO). Adequacy of inflow can be assessed by hemodynamic measures, angiography or other imaging modalities obtained during Screening or recorded in the medical records up to 30 days prior to the Screening Visit or as defined by imaging at the time of the procedure. A patient with inadequate inflow at the time of Screening can still be enrolled if the inflow is addressed and resolved by the planned revascularization procedure.
  5. Diagnosis of PAD confirmed by history and any one of the following observed in the index (intervention) leg at the Screening Visit:

    1. Resting ABI ≤0.90, or
    2. In patients with an ABI > 1.40 (non-compressible vessels) a resting GTI \<0.70 can be used for inclusions.
  6. Patient has been advised of the beneficial effects of smoking cessation and exercise therapy but is not in the process of changing their smoking status or exercise at the time of the Screening Visit.

Exclusion criteria

Exclusion Criteria

  1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
  2. Revascularisation planned only to treat proximal (inflow) disease in the iliac and/or common femoral arteries.
  3. Previous randomisation in the present study.
  4. Participation in another clinical study with an product within the last 3 months or any new clinical trial during the course of this study.
  5. Gangrene or ischemic ulcer of either lower extremity.
  6. PAD of a non-atherosclerotic nature.
  7. Clinical necessity to use dual antiplatelet therapy within 7 days prior to randomisation, or single anti- therapy (ticlopidine, prasugrel, vorapaxar, ticagrelor or dipyridamole) other than clopidogrel or aspirin. Clopidogrel or aspirin can be taken up to and including the time that the loading dose is being given.
  8. Clinical necessity to use the following restricted concomitant medications within 4 weeks prior to randomisation. Patients taking any of these medications at the Screening Visit may be considered for randomisation after a 4 week from the medication.

    1. Pentoxifylline or cilostazol for relief of claudication symptoms
    2. Chronic oral or parenteral anticoagulant therapy (greater than 7 days)
    3. Strong inhibitors of enzymes (Section 5.6.9.1)
    4. Strong inducers of CYP3A enzymes (Section 5.6.9.2)
    5. Simvastatin or lovastatin at daily doses over 40 mg
  9. Any disease process (e.g. angina, cardiac abnormality, congestive heart failure (CHF), (COPD), respiratory disease, obesity, stroke, severe neuropathy of the foot, symptomatic musculoskeletal disease of the lower extremity), other than PAD, that would interfere with exercise performance during the ETT or prevent the patient from reaching their claudication-limited PWT as the primary endpoint of the study.
  10. Coronary, aortic surgery, angioplasty, lumbar sympathectomy or lower extremity surgery that impacts the ability to walk on a treadmill within the past 3 months prior to EVR. Revascularization of the non-index lower extremity within the past 4 weeks prior to EVR.
  11. Any major lower limb amputation due to PAD anticipated within the next 3 months or prior major amputation due to PAD (minor toe amputations allowed if it does not interfere with ambulation).
  12. Myocardial infarction or stroke in the previous 3 months.
  13. Any concomitant disease process with a of less than 1 year or which is sufficiently severe as to compromise the validity of test performance.
  14. Dementia likely to jeopardise understanding of information pertinent to study conduct or compliance to study procedures.
  15. Concern for the inability of the patient to comply with study procedures and/or followup (e.g., alcohol or drug abuse).
  16. Resting systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥95 mmHg at the Screening Visit, in spite of antihypertensive treatments allowed by the protocol.
  17. A known bleeding diathesis, haemostatic or coagulation disorder, or systemic bleeding, whether resolved or ongoing.
  18. Known severe liver disease (e.g., ascites and or clinical signs of coagulopathy).
  19. Renal failure requiring dialysis.
  20. History of previous intracranial bleed at any time, gastrointestinal bleed within the past 6 months, or major surgery within 30 days (if the surgical wound is judged to be associated with an increased risk of bleeding).
  21. History of thrombocytopenia or neutropenia.
  22. to ticagrelor, aspirin or lactose.
  23. Initiation of antidiabetic, antihypertensive, lipid-lowering and beta-blocking drugs within 1 month prior to the Screening Visit.
  24. Pregnancy, lactation, fertility without protection against pregnancy (for women of ; a urine or serum pregnancy test will be performed at the Screening Visit).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Ticagrelor

    26 Weeks of ticagrelor 90mg twice a day plus aspirin placebo once daily

    Drug: Ticagrelor

  • Active comparator
    Aspirin

    26 Weeks of aspirin 100mg once daily plus ticagrelor placebo twice a day

    Drug: Comparator

Interventions

  • Antiplatelet therapy approved for ACS. Antagonist of P2Y12 and inhibitor of adenosine diphosphate (ADP)-induced platelet aggregation.

    Also known as: Brilinta

  • Aspirin monotherapy anti-platelet treatment for PAD patients following EVR procedures

    Also known as: Aspirin

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Log Transformed Peak Walking Time (PWT) at Week 26 or Early Termination (ET)

    Time frame: 26 Weeks

Secondary outcomes

  1. Change From Baseline in Log Transformed Claudication Onset Time (COT) at Week 26 or Early Termination (ET)

    Time frame: 26 Weeks

07

Results

Posted Jun 14, 2017
Limitations and caveats
This study was terminated early for low enrolment. Less than 25% of anticipated number of subjects were enroled and there was an imbanlance between groups. Therefore, the results should be interpreted with caution.

Participant flow

A total of 71 subjects were screened at 16 centers throughout the United States of America (USA). First subject enrolled: 20Oct2014. Last subject last visit: 23May2016. Date of early study termination: 21Oct2015

Participant flow — Overall Study
MilestoneTicagrelorAspirin
Started1624
Sujects who received treatment1624
Sujects who completed treatment1017
Completed1420
Not completed24
Withdrew: No evr/not pad/pi decision/rle bypass04
Withdrew: Lost to follow-up10
Withdrew: Adverse event10

Outcome measures

PrimaryChange From Baseline in Log Transformed Peak Walking Time (PWT) at Week 26 or Early Termination (ET)
Time frame:
26 Weeks
Reported as:
Mean · log(Second)
Change From Baseline in Log Transformed Peak Walking Time (PWT) at Week 26 or Early Termination (ET)
log(Second)TicagrelorAspirin
Change From Baseline in Log Transformed Peak Walking Time (PWT) at Week 26 or Early Termination (ET)0.0 (-0.2 to 0.2)0.1 (-0.0 to 0.3)
Statistical analysis
  • Ticagrelor vs Aspirin · t-test, 2 sided · p = 0.3441 · Mean difference (net): -0.1 · 95% CI -0.4 to 0.1Difference is Ticagrelor - Aspirin. LOCF was used for missing data imputation.
SecondaryChange From Baseline in Log Transformed Claudication Onset Time (COT) at Week 26 or Early Termination (ET)
Time frame:
26 Weeks
Reported as:
Mean · log(Second)
Change From Baseline in Log Transformed Claudication Onset Time (COT) at Week 26 or Early Termination (ET)
log(Second)TicagrelorAspirin
Change From Baseline in Log Transformed Claudication Onset Time (COT) at Week 26 or Early Termination (ET)0.6 (0.1 to 1.1)0.5 (0.1 to 0.8)
Statistical analysis
  • Ticagrelor vs Aspirin · t-test, 2 sided · p = 0.6186 · Mean difference (net): 0.1 · 95% CI -0.4 to 0.6Difference is Ticagrelor - Aspirin. LOCF was used for missing data imputation.

Adverse events

Collected over 26 weeks treatment period + 30 days followup. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ticagrelor—4/16 (25%)1/16 (6.3%)
Aspirin—2/24 (8.3%)1/24 (4.2%)
Most frequent serious events
Most frequent serious events
EventTicagrelorAspirin
Coronary artery diseaseCardiac disorders1/160/24
SyncopeNervous system disorders1/160/24
HaemorrhageVascular disorders1/160/24
HypotensionVascular disorders1/160/24
CellulitisInfections and infestations0/161/24
OsteomyelitisInfections and infestations0/161/24
Skin ulcerSkin and subcutaneous tissue disorders0/161/24
Peripheral artery stenosisVascular disorders0/161/24
Most frequent other events
Most frequent other events
EventTicagrelorAspirin
Procedural haemorrhageInjury, poisoning and procedural complications1/160/24
Arterial occlusive diseaseVascular disorders0/161/24

Baseline characteristics

All randomised subjects with the exception of one subject who did not undergo EVR.

Age, Continuous
Age, Continuous(years)TicagrelorAspirinTotal
Mean69.1 ± 9.1567.0 ± 8.3167.9 ± 8.60
Sex: Female, Male
Sex: Female, Male(Participants)TicagrelorAspirinTotal
Female9918
Male71522
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TicagrelorAspirinTotal
Hispanic or Latino336
Not Hispanic or Latino132134
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TicagrelorAspirinTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American426
White112031
More than one race000
Unknown or Not Reported123
08

Study locations

10 sites
  • Research Site
    Daytona Beach, Florida 32114, United States
  • Research Site
    Jacksonville, Florida 32216, United States
  • Research Site
    Ocala, Florida 34471, United States
  • Research Site
    Sarasota, Florida 34239, United States
  • Research Site
    Munster, Indiana 46321, United States
  • Research Site
    New York, New York 10001, United States
  • Research Site
    Yonkers, New York 10701, United States
  • Research Site
    Cleveland, Ohio 44195, United States
  • Research Site
    McKinney, Texas 75069, United States
  • Research Site
    San Antonio, Texas 78229, United States
09

References and documents

Publications

  • Rogers RK, Hiatt WR, Patel MR, Shishehbor MH, White R, Khan ND, Bhalla NP, Jones WS, Low Wang CC. Ticagrelor in Peripheral Artery Disease Endovascular Revascularization (TI-PAD): Challenges in clinical trial execution. Vasc Med. 2018 Dec;23(6):513-522. doi: 10.1177/1358863X18760996. Epub 2018 Apr 9. PubMed 29629845 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2014 to primary completion in May 2016, 19 months.

Results were first posted in Jun 2017, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2014
First posted
Aug 28, 2014
StartActual
Oct 20, 2014
Primary completionActual
May 23, 2016
CompletionActual
May 23, 2016
Results first posted
Jun 14, 2017
Last update
Jul 19, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02227368
Lead sponsor
AstraZeneca
Collaborators
CPC Clinical Research
Responsible party
Sponsor
First posted
Aug 28, 2014
Start date
Oct 20, 2014
Primary completion
May 23, 2016
Completion
May 23, 2016
Results posted
Jun 14, 2017
Last update
Jul 19, 2017

Study contacts

William Hiatt, MD
principal investigator · Colorado Prevention Center Clinical Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ticagrelor

Start the discussion